PHASE Scientific Fuels Diagnostics Revolution with $34M Series A Investment in PHASIFY™ Technology Advancement

PHASE Scientific International Limited is thrilled to announce that it has successfully raised $34,000,000 in funding, marking a significant milestone in its mission to inspire a new state of health. As a high-growth biotech company headquartered in Hong Kong and expanded across Southern California and China's Greater Bay Area, PHASE Scientific is dedicated to revolutionizing healthcare through better insight. With this capital infusion, the company will further enhance its research and development efforts to refine and expand its suite of diagnostic tools, including its groundbreaking proprietary technology, PHASIFY™. This innovative platform redefines the gold standard of diagnostics by enabling quicker, easier, and more precise detection of target molecules—concentrating them 10-100 times more effectively than traditional methods—to uncover hidden conditions that may otherwise be overlooked. The significant investment will accelerate the deployment of advanced diagnostics for cancer and infectious diseases, making tests more affordable, accessible, and accurate. Furthermore, the funding will bolster the development of complementary products and services such as INDICAID™, at-home rapid tests designed for convenience and reliability, and the PHASE lab, a state-of-the-art facility dedicated to comprehensive diagnostic support. By investing in these pioneering initiatives, PHASE Scientific solidifies its commitment to supporting individuals throughout their integrated healthcare journey—from early screening and diagnostics to treatment and continuous monitoring—paving the way for a healthier future for all. This funding marks an exciting milestone for the company, reinforcing its vision to champion early detection and proactive healthcare management, and catalyzing its efforts to transform the diagnostic landscape worldwide.